U.S. Markets closed

Geron to Present at Two Conferences, Stock Jumps 13%

Peter Neil

Biotechnology Stocks Fall to Close the Month

(Continued from Prior Part)

IBB’s small-cap stocks return 10% in November 2015

The iShares NASDAQ Biotechnology ETF’s (IBB) small-cap stocks gave a return of -0.85% on November 30, 2015, outperforming IBB but underperforming the SPDR S&P 500 ETF (SPY). As of November 30, 2015, IBB holds 79 small-cap stocks, with market caps in the range of less than $2 billion to $300 million. Out of the 79 small-cap stocks, 25 stocks gave positive returns and 54 stocks ended up in the red. Small-cap stocks account for ~9.9% of IBB’s portfolio. IBB’s small-cap stocks include Sarepta Therapeutics (SRPT), Ironwood Pharmaceuticals (IRWD), and Achillion Pharmaceuticals (ACHN), which gave returns of -1.7%, -0.5%, and 0.3%, respectively.


The above graph reflects the performance of IBB’s small-cap stocks compared with IBB and SPY. For the month of November, IBB’s small-cap stocks have outperformed IBB and SPY, with IBB’s small-cap stocks returning 10.1%, IBB returning 2.8%, and SPY returning 0.37%.

Geron to present in two conferences, stock jumps 13%

Geron (GERN) rose by 13.6% on November 30, 2015. According to its press release, Geron announced that “John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:

  • Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015.
  • Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015.

Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting. The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015. ”

Geron closed at $5.10 and was trading above its 20-, 50-, and 100-day moving averages. Geron’s RSI (relative strength index) stood at 74, indicating that the stock is overbought. Geron has a book value of $0.93 per share. With its current price, the stock is trading at a PBV (price-to-book value) ratio of 5.5x. Geron has a weight of 0.1% in IBB’s portfolio.

Continue to Next Part

Browse this series on Market Realist: